MedTrace Logo

Dose Response Study of a Topical Gel for the Treatment of Raynaud's Phenomenon

NCT00378521 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2007-05-30

No results posted yet for this study

Summary

The Purpose of this study is to determine the response to two different strengths of a topical gel containing nitroglycerin in patients with Raynaud's disease.

Conditions

  • Raynaud's Disease
  • Raynaud's Disease Secondary to Scleroderma
  • Raynaud's Disease Secondary to Autoimmune Disease

Interventions

DRUG

MQX-503

Sponsors & Collaborators

  • MediQuest Therapeutics

    lead INDUSTRY

Principal Investigators

  • Leslie Klaff, MD · Rainier Clinical Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-07-31
Completion
2006-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00378521 on ClinicalTrials.gov